Bioxytran Unveils Revolutionary Precision Diagnostics on Tissue Oxygenation
Bioxytran (OTCQB: BIXT) announced a significant scientific advancement with the publication of a groundbreaking book by Prof. Avraham Mayevsky on tissue oxygenation and mitochondrial function. The research highlights the limitations of current peripheral oxygen measurements and introduces a paradigm shift towards tissue-specific oxygenation monitoring.
The company's MDX Viewer technology, combined with their Universal Oxygen Carrier (UOC) and BXT-25 development programs, aims to revolutionize treatment approaches for conditions like stroke and Alzheimer's disease. The technology will serve as a crucial biomarker in upcoming BXT-25 clinical trials, potentially transforming how oxygen delivery is measured and managed in critical conditions.
Bioxytran (OTCQB: BIXT) ha annunciato un importante avanzamento scientifico con la pubblicazione di un libro rivoluzionario del Prof. Avraham Mayevsky sulla ossigenazione tissutale e la funzione mitocondriale. La ricerca evidenzia i limiti delle attuali misurazioni periferiche dell'ossigeno e propone un cambio di paradigma verso il monitoraggio dell'ossigenazione specifico per i tessuti.
La tecnologia MDX Viewer della società, unita al loro Universal Oxygen Carrier (UOC) e ai programmi di sviluppo BXT-25, mira a rivoluzionare gli approcci terapeutici per patologie come ictus e morbo di Alzheimer. La tecnologia fungerà da biomarcatore cruciale nei prossimi trial clinici BXT-25, potenzialmente trasformando il modo in cui la somministrazione di ossigeno viene misurata e gestita nelle condizioni critiche.
Bioxytran (OTCQB: BIXT) anunció un importante avance científico con la publicación de un libro innovador del Prof. Avraham Mayevsky sobre la oxigenación tisular y la función mitocondrial. La investigación subraya las limitaciones de las mediciones periféricas actuales de oxígeno e introduce un cambio de paradigma hacia el monitoreo de la oxigenación específico por tejido.
La tecnología MDX Viewer de la compañía, combinada con su Universal Oxygen Carrier (UOC) y los programas de desarrollo BXT-25, pretende revolucionar los enfoques terapéuticos para condiciones como el ictus y la enfermedad de Alzheimer. La tecnología servirá como un biomarcador clave en los próximos ensayos clínicos BXT-25, con el potencial de transformar la forma en que se mide y gestiona la entrega de oxígeno en situaciones críticas.
Bioxytran (OTCQB: BIXT)는 조직 산소화와 미토콘드리아 기능에 관한 Avraham Mayevsky 교수의 획기적인 저서 발간으로 중요한 과학적 진전을 발표했습니다. 해당 연구는 현재 말초 산소 측정의 한계를 강조하고 조직 특이적 산소화 모니터링으로의 패러다임 전환을 제시합니다.
회사의 MDX Viewer 기술은 Universal Oxygen Carrier(UOC)와 BXT-25 개발 프로그램과 함께 뇌졸중 및 알츠하이머병과 같은 질환에 대한 치료 접근법을 혁신하는 것을 목표로 합니다. 이 기술은 향후 BXT-25 임상시험에서 중요한 바이오마커로 사용되어 중증 상황에서 산소 전달을 측정하고 관리하는 방식을 바꿀 가능성이 있습니다.
Bioxytran (OTCQB: BIXT) a annoncé une avancée scientifique majeure avec la publication d'un ouvrage révolutionnaire du Prof. Avraham Mayevsky sur l'oxygénation tissulaire et la fonction mitochondriale. La recherche souligne les limites des mesures périphériques d'oxygène actuelles et introduit un changement de paradigme vers la surveillance de l'oxygénation spécifique aux tissus.
La technologie MDX Viewer de la société, combinée à leur Universal Oxygen Carrier (UOC) et aux programmes de développement BXT-25, vise à révolutionner les approches thérapeutiques pour des affections telles que l'accident vasculaire cérébral et la maladie d'Alzheimer. La technologie servira de biomarqueur crucial dans les prochains essais cliniques BXT-25, pouvant transformer la façon dont l'apport en oxygène est mesuré et géré dans les situations critiques.
Bioxytran (OTCQB: BIXT) gab einen bedeutenden wissenschaftlichen Fortschritt bekannt: die Veröffentlichung eines wegweisenden Buches von Prof. Avraham Mayevsky über Gewebeoxygenierung und Mitochondrienfunktion. Die Forschung hebt die Grenzen aktueller peripherer Sauerstoffmessungen hervor und schlägt einen Paradigmenwechsel hin zu gewebespezifischem Oxygenierungs-Monitoring vor.
Die MDX Viewer-Technologie des Unternehmens, kombiniert mit dem Universal Oxygen Carrier (UOC) und den Entwicklungsprogrammen BXT-25, zielt darauf ab, Behandlungsansätze bei Erkrankungen wie Schlaganfall und Alzheimer zu revolutionieren. Die Technologie wird als wichtiger Biomarker in kommenden BXT-25-Studien dienen und könnte die Messung und Steuerung der Sauerstoffzufuhr in kritischen Zuständen grundlegend verändern.
- Development of advanced tissue-specific oxygenation monitoring technology
- Integration of MDX Viewer technology as a biomarker for BXT-25 clinical trials
- Potential applications in major markets including stroke and Alzheimer's treatment
- Clinical trials for BXT-25 still pending
- Technology remains in development phase with no immediate revenue generation
- Game changer for stroke, Alzheimer’s, and beyond
- Shifting from peripheral to tissue-specific oxygenation monitoring
BOSTON, MASSACHUSETTS, Aug. 15, 2025 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a pioneering clinical stage biotechnology company at the forefront of oxygen therapeutics, is proud to announce a major scientific milestone: the publication of Body Oxygen Homeostasis and Mitochondrial Function from Animal Models to Clinical Applications by Prof. Avraham Mayevsky, a key advisor to Bioxytran. This groundbreaking work dives deep into the science of oxygen regulation and mitochondrial health – revealing transformative insights that could redefine treatment for stroke, Alzheimer’s, and other critical conditions.
https://link.springer.com/book/10.1007/978-3-031-94113-9
Current medical practices rely on outdated peripheral oxygen measurements, often missing the real crisis happening inside vital organs. Imagine a stroke patient with "
Bioxytran is integrating these insights into its upcoming BXT-25 clinical trials, aiming to prove that targeted oxygen delivery can rescue damaged tissues—and potentially rewrite treatment paradigms. This technology will serve as a biomarker capable of advancing the clinical trials of BXT-25 because it is a powerful way to measure oxygen consumption of the brain during stroke.
"Bioxytran is poised to lead the oxygen therapeutics revolution," said Avraham Mayevsky, Member of Bioxytran’s Medical Advisory Board. "The principles in this book, tracing tissue oxygenation, could accelerate treatments for stroke, chronic wounds, and even Alzheimer’s—where restoring oxygen delivery may slow neurodegeneration."
About Bioxytran, Inc.
Bioxytran, Inc. is at the forefront of developing complex carbohydrate-based therapeutics to address critical unmet medical needs in its three core platform technologies. These include virology, cancer metastasis, and oxygen transport. In addition to ProLectin-M, Bioxytran is advancing programs for pulmonary fibrosis and stroke treatment. When utilized by paramedics at the time of diagnosis BXT-25 has the possibility of reducing what is known as the time until needle by over
Investor Relations
Michael Sheikh
509-991-0245
mike.sheikh@bioxytraninc.com
Forward-Looking Statements
This press release includes forward-looking statements as defined under federal law, including those related to the performance of technology described in this press release. These forward-looking statements are generally identified by the words “believe,” “expect,” “anticipate,” “estimate,” “intend,” “plan,” and similar expressions, although not all forward-looking statements contain these identifying words. Such statements are subject to significant risks, assumptions and uncertainties. Known material factors that could cause Bioxytran’s actual results to differ materially from the results contemplated by such forward-looking statements are described in the forward-looking statements and risk factors in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and those risk factors set forth from time-to-time in other filings with the Securities and Exchange Commission. Bioxytran undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events, or otherwise, except to the extent required under federal securities laws.
FAQ
What is Bioxytran's (BIXT) new breakthrough in tissue oxygenation monitoring?
How will BIXT's technology impact stroke treatment?
What markets is Bioxytran (BIXT) targeting with its oxygen monitoring technology?
Who is Prof. Avraham Mayevsky and what is his role at Bioxytran (BIXT)?
What is the significance of Bioxytran's MDX Viewer technology?
